ERAS compared with MAZE: revenue, margins and what each company keeps, and the suppliers and customers both name

ERASErasca, Inc.

Mkt capRevenueRevenue

MAZEMaze Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ERASErasca, Inc.

MAZEMaze Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ERAS

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.2%▲+1.47%×0.11

May 12 '26±8.4%▼−0.57%×0.07

Q1 FY26±11.1%▼−7.03%×0.63

Jan 21 '26±19.7%▲+2.45%×0.13

MAZE

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±16.0%▲+0.81%×0.05

May 13 '26±9.4%▲+4.58%×0.49

= impliedERAS realized, solidMAZE realized, hatchedOne scale, both sides: full bar = 39%× = |realized| ÷ impliedSource: market data

Q1 FY26

±38.2%

▼−35.24%

×0.92

Q3 FY25±14.2%▼−3.48%×0.25

ERASErasca, Inc.

14.03▼−2.26%

Mkt cap$5.0BRevenue—

MAZEMaze Therapeutics, Inc.

29.99▼−4.75%

Regular sessionNov 2 '26

Mkt cap$1.9BRevenue$20MQ1 FY26

Compare

Regular sessionNov 2 '26

ERASErasca, Inc.

MAZEMaze Therapeutics, Inc.

14.03▼−2.26%

Price

29.99▼−4.75%

$5.0B

Mkt cap

$1.9B

—

Revenue

$20MQ1 FY26

ERAS14.03▼−2.26%vsMAZE29.99▼−4.75%Regular sessionNov 2 '26